AstraZeneca Returns To Growth But Coronavirus Likely To Hit China Revenues
AstraZeneca Returns To Growth, But Coronavirus Likely To Hit China Revenues
00:36 EST 14 Feb 2020 |
SCRIP
A long turnaround process now complete, AstraZeneca could hit double digit growth in 2020, thanks to existing products and new...
More From BioPortfolio on "AstraZeneca Returns To Growth, But Coronavirus Likely To Hit China Revenues"